Certain features of will be down for maintenance the evening of Friday August 18th starting at 8:00 pm CDT until Saturday August 19th at 12:01 pm CDT.   Please note that you still have telephone and email access to our local offices. We apologize for any inconvenience.

Parkinson's Disease

By: Carolyn L. Crankshaw, BioFiles v7 n2, 2011, 16–20

BioFiles Volume 7, Number 2 — Neurodegenerative Diseases

Download BioFiles v7 n2 (13.0 Mb PDF)

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting more than 6 million people worldwide. PD is a slowly progressing motor system neurodegeneration characterized by akinesia, rigidity and resting tremor. Neuropathologically PD is characterized by loss of dopaminergic cell bodies in the substantia nigra, resulting in a reduced supply of dopamine to the basal ganglia. The high metabolic rate of the substantia nigra combined with high content of oxidizable species and iron, high levels of reactive oxygen species (ROS) and low level of antioxidants, all serve to initiate and propagate apoptosis of the dopaminergic neurons.

Mutations in the a-synuclein gene (SNCA) occur in familial cases of Parkinson's disease, pointing to a role for this gene in PD. a-Synuclein can form protein aggregates with additional cytoskeletal proteins including synaptophysin (SYP) and Tau (MAPT), which are believed to lead to the pathogenesis of Lewy body formation.

Synphilin (SNCAIP) interacts with α-synuclein in neuronal tissue and is thought to play a role in the formation of cytoplasmic inclusions and neurodegeneration. A mutation in this gene has been associated with Parkinson's disease.

Mutations in the LRRK2 (PARK8) gene are found in about 5-6 percent of all familial cases as well as 2 percent of cases with no known cause. Interestingly, this mutation can cause early-onset Parkinson's in families from diverse ethnic backgrounds, in a form that is identical in clinical symptoms to late-onset Parkinson's. LRRK2 encodes a protein that is part of a larger multidomain protein with characteristic GTPase and kinase domains. LRRK2's substrates, its binding partners and its regulators have yet to be confirmed or clarified, and consequently its role in normal physiological functions in the cell and in disease are still largely unknown.

Loss of function mutations in the Parkin (PARK2), PINK1 (PARK6) and PARK7 (DJ-1) genes resulting in functionally inactive proteins, underlie common forms of autosomal-recessive PD. Patients with lossof- function Parkin mutations account for an estimated 40-50 percent of all familial earlyonset cases of PD, whereas mutations in PINK1 and PARK7 are less common. Several studies have demonstrated that products of all three recessive genes preserve mitochondrial functions, protect against reactive oxygen species, or play a role in protein degradation pathways. Normally, Parkin tags proteins with ubiquitin for degradation via the proteasome. Mutations in the Parkin gene lead to a loss of this activity. DJ-1 is a molecular chaperone involved in protein folding, as well as in other functions. It is found in the cytosol, the mitochondrial matrix and intermembrane space. It regulates redox-dependent signaling pathways and acts as a regulator of antioxidant gene expression.

UCHL1 (PARK5) is a member of the ubiquitin- C-terminal hydrolases. Expression of UCHL1 is highly specific to neurons and to cells of the diffuse neuroendocrine system and their tumors. A point mutation I93M in this protein is implicated as the cause of PD. Furthermore, a polymorphism S18Y in this gene has been found to be associated with a reduced risk for Parkinson's disease. UCH-L1 is also associated with the Alzheimer's disease.

The ATP13A2 (PARK9) gene encodes a member of the P5 subfamily of ATPases which transports inorganic cations as well as other substrates. Mutations in this gene are associated with Kufor-Rakeb syndrome (KRS), also referred to as Parkinson disease 9, and in juvenile forms of PD.

Additional genes, including GIGYF2 (PARK11), HTRA2 (OMI, PARK13) PLA2G6 (PARK14), FBXO7 (PARK15), STUB1 (CHIP) and RNF19A (Dorfin) are thought to be implicated in PD.

With its complex etiology and impact on millions, Parkinson's Disease continues to be the subject of intensive research effort.




  1. Pawlyk, A.C., et al. Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J. Biol. Chem. 2003, 278, 48120-48128.
  2. Kitada, T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998, 392, 605-608.
  3. Maroteaux, L., and Scheller, R.H. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Mol. Brain. Res. 1991, 11, 335-343.
  4. Ueda, K., et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 1993, 90, 11282-11286.
  5. Kurihara, L.J., et al. Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia. Hum. Mol. Genet. 2001, 10, 1963-1970.
  6. Leroy, E., et al. The ubiquitin pathway in Parkinson's disease. Nature. 1998, 395, 451-452.
  7. Levecque, C., et al. No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease. J. Neural Transm. 2001, 108, 979-984.
  8. Liu, Y., et al. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell. 2002, 111, 209-218.
  9. Lee, G., et al. Synphilin-1 degradation by the ubiquitinproteasome pathway and effects on cell survival. J. Neurochem. 2002, 83, 346-352.
  10. Nagano, Y., et al. Siah-1 facilitates ubiquitination and degradation of synphilin-1. J. Biol. Chem. 2003, 278, 51504-51514.
  11. Liani, E. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc. Natl. Acad. Sci. USA. 2004, 101, 5500-5505.
  12. Arai, R., et al. Differential subcellular location of mitochondria in rat serotonergic neurons depends on the presence and the absence of monoamine oxidase type B. Neurosci. 2002, 114, 825-835.
  13. Fernandez, H.H., and Chen, J.J. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin. Neuropharmacol. 2007, 30, 150-168.
  14. Hishikawa, N., et al. Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis. Am. J. Pathol. 2003, 163, 609-619.
  15. Ito, T., et al. Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1. J. Biol. Chem. 2003, 278, 29106-29114.
  16. Paisan-Ruiz, C., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004, 44, 595-600.
  17. West, A.B., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA. 2005, 102, 16842-16847.
  18. Cookson, M.R., et al. The roles of kinases in familial Parkinson's disease. J. Neurosci. 2007, 27, 11865-11868.
  19. Valente, E.M., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004, 304, 1158-1160.
  20. Beilina, A., et al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl. Acad. Sci. USA. 2005, 102, 5703-5708.
  21. Park, J., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature. 2006, 441, 1157-1161.
  22. Torres, G.E., et al. Plasma membrane monoamine transporters: structure, regulation and function. Nature Rev. Neurosci. 2003, 4, 13-25.
  23. Ciliax, B.J., et al. Immunocytochemical localization of the dopamine transporter in human brain. J. Comp. Neurol. 1999, 409, 38-56.
  24. Gandhi, S., et al. PINK1 protein in normal human brain and Parkinson's disease. Brain. 2006, 129, 1720-1731.
  25. Ramirez, A., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nature Genet. 2006, 38, 1184-1191.
  26. Wei, J., et al. Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies. J. Biol. Chem. 2007, 282, 28904-28914.
  27. Ning, Y.P., et al. PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype. Neurol. 2008, 70, 1491-1493.
  28. Hod, Y. Differential control of apoptosis by DJ-1 in prostate benign and cancer cells. J. Cell. Biochem. 2004, 92, 1221-1233.
  29. Bonifati, V., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003, 299, 256-259.
  30. Faccio, L., et al. Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia. J. Biol. Chem. 2000, 275, 2581-2588.
  31. Strauss, K.M., et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet. 2005, 14, 2099-2111.
  32. Park, H.J., et al. Beta-amyloid precursor protein is a direct cleavage target of HtrA2 serine protease. Implications for the physiological function of HtrA2 in the mitochondria. J. Biol. Chem. 2006, 281, 34277-34287.
  33. Morgan, N.V., et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 2006, 38, 752-754.
  34. Gregory, A., et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurol. 2008, 71, 1402-1409.
  35. Schaeffer, E.L., and Gattaz, W.F. Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacol. 2008, 198, 1-27.
  36. Petrucelli, L., et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 2004, 13, 703-714.
  37. Shin, Y., et al. The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alphasynuclein degradation decisions between proteasomal and lysosomal pathways. J. Biol. Chem. 2005, 280, 23727-23734.
  38. Miller, V.M., et al. CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J. Neurosci. 2005, 25, 9152-9161.


Related Links